SillaJen, Inc. (KOSDAQ:215600)
South Korea · Delayed Price · Currency is KRW 2,920.00
+85.00 (3.00%)
Aug 13, 2025, 3:30 PM KST
SillaJen Company Description
SillaJen, Inc. develops and commercializes oncolytic immunotherapy products in South Korea.
Its lead product is Pexa-Vec for the treatment of solid tumors and induction of cancer specific antibodies.
The company also develops BAL0891, a dual TTK/PLK inhibitor; SJ-600 to improve the intravenous administration efficiency of anticancer viruses; JX-970 for the treatment of tumor tissues; and JX-900 is a series of modified vaccinia vaccine.
SillaJen, Inc. was founded in 2006 and is headquartered in Seoul, South Korea.
SillaJen, Inc.
| Country | South Korea |
| Founded | 2006 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 37 |
| CEO | Jaekyung Kim |
Contact Details
Address: 109, Sogong-ro Seoul, 04525 South Korea | |
| Phone | 82 2 368 2600 |
| Website | sillajen.com |
Stock Details
| Ticker Symbol | 215600 |
| Exchange | KOSDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | KRW |
| ISIN Number | KR7215600008 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Jaekyung Kim | Chief Executive Officer |
| Suk Song Myung | Chief Financial Officer |